Bausch + Lomb Corp.
Valuation each multiple against its own 5-year range
Vs. peers Medical Instruments & Supplies
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Bausch + Lomb Corp. (BLCO) | 6.93B | -60.56 | 1.08 | 0.00% |
| Intuitive Surgical (ISRG) | 138.33B | 48.25 | 8.65 | 0.00% |
| Becton Dickinson & Co (BDX) | 57.96B | 52.02 | 2.35 | 1.97% |
| Alcon (ALC) | 35.92B | 54.24 | 1.64 | 0.48% |
| ResMed (RMD) | 33.14B | 21.46 | 5.57 | 1.04% |
| Medline (MDLN) | 32.55B | 57.52 | 2.76 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 2.0% above Morningstar's fair value estimate.
Analyst note
Bausch & Lomb reported $1.4 billion in revenue, up 8% at constant currency, and adjusted earnings per share of $0.34 during the third quarter. Results were mixed, with revenue modestly below FactSet consensus and EPS exceeding expectations. Shares are up 8%.
Why it matters: Strong momentum in both dry eye (up 22%), driven by Miebo and Xiidra, and implantables (up 42%) continues to reinforce B&L’s shift to higher-margin premium categories. This shift contributed to a 460-basis-point increase in adjusted EBITDA margin since last year. Management once again raised guidance, now for the third time this year, increasing the midpoints for revenue and adjusted EBITDA by roughly low-single-digit percentages to $5.5 billion and adjusted EBITDA of $1.15 billion, respectively. Strong execution and healthy demand in the eye market drove the raise. Resilient demand across key eye-care categories and international markets has helped B&L benefit from secular fundamentals and consumer trends, as reflected in management’s commentary and raised guidance.
The bottom line: We are raising our fair value to $19/CAD 26.50 from $18.50/CAD 25.50 for narrow-moat B&L, driven by the guidance refresh and strong cash flow generation. Shares have recovered from last week’s pullback, and we believe they are currently fairly valued. Management declined to provide any additional details about former CEO Brent Saunders’ departure beyond what the press release initially included. Although Thomas Appio has the industry experience to run B&L smoothly in the interim, we believe it may be tough to balance two companies simultaneously. We highlight our High Uncertainty Rating for B&L as we await a permanent leader.
We believe today’s impressive share movement is driven primarily by investors giving the firm credit for its progress in building a comprehensive eye-care product suite, supported by recent launches and new commitments from investor days that appear increasingly attainable as the year progresses. Given the uncertainty around the CEO position and its overhang on the shares, we view this movement as extremely positive. Year to date, B&L shares have traded up 17%, outperforming the Morningstar Global Medical Devices Index by roughly 30%.
Fair value
Following the results of the third fiscal quarter of 2026, we raise our fair value estimate for narrow-moat Bausch & Lomb to $19 per share from $18.50 after accounting for the latest sales and adjusted EBITDA guidance, which was raised by a low single-digit percentage, and recent cash flows.
Over the long term, we forecast mid-single-digit growth for vision care. We believe macro drivers, including an aging population, rising myopia prevalence, and a favorable product mix, should provide solid tailwinds. Because roughly three-quarters of contact lens wearers are aged 25 and older, an aging population helps expand B&L’s end markets. Studies have suggested that roughly 30%-40% of the population is myopic today, but this number is expected to rise to 50% by 2050, and we expect the contact lens market to grow accordingly. We also believe a trend to a more favorable product mix will fuel the company’s margin expansion. The industry has seen an increasing portion of contact lens wearers upgrade their lenses based on modality, lens material, and lens type. Fifteen years ago, daily lens sales made up about 12% of the overall lens market, but they now make up more than half. We also see wearers upgrading their lenses from nonsilicone hydrogel to silicone hydrogel, or SiHy. SiHy lenses made up roughly 45% of all contact lenses 15 years ago, but that number has jumped to roughly 60% today, and we expect it to continue to rise. Advancements in specialty lenses and a growing adoption of toric and multifocal lenses will benefit B&L, as they have a material pricing premium over spherical lenses. We believe a combination of these factors can bolster B&L’s sales and operating margin.
Outside of contact lenses, we believe B&L is well positioned to enjoy low- to mid-single-digit sales growth for lens solutions and over-the-counter eye care and supplements. With products like Lumify and PreserVision, B&L is a market leader in many spaces it serves. We expect the company to maintain its dominance over the next five years because of patents, product superiority, and customer preferences.
Surgical makes up about 20% of B&L’s total sales, and we forecast low-single-digit long-term growth for the segment. After years of underinvestment in the business while B&L was under its former parent company, we have seen a greater focus on innovating the segment after the spinoff. B&L has a number of intraocular lenses, or IOLs, including enVista and Akeros, but it has consistently lagged behind Alcon and Johnson & Johnson, two of its close competitors in the space. And we see B&L's presence in the space under more pressure as its two competitors both offer a number of advanced-technology IOLs, or ATIOLs, an area where B&L lacks advanced products. While we don’t see this as a significant threat over the short term because most ATIOLs, unlike monofocal IOLs, are not covered by insurance, we have seen a greater adoption of ATIOLs during cataract surgeries over the years. If B&L continues to lag behind its competition, it could lose its foothold in the IOL space. Besides IOLs, B&L also manufactures ophthalmic surgical equipment as well as surgical instruments. The lifecycle for surgical equipment is around 10 years, and B&L launched its phacoemulsification machine, Stellaris Elite, in 2017, so we expect a new machine within the next few years.
For ophthalmic pharmaceuticals, we model mild year-on-year growth for the segment thanks to continued prescription growth in both Xiidra and Miebo. We think the firm should continue to reap the fruits of its marketing campaigns for both drugs and expect nice margin benefits over the midterm.
Economic moat
We assign Bausch & Lomb a narrow moat because we believe the firm's strong brand recognition and technically advanced products (intangibles), and patients’ unlikeness to move to a different product (switching costs) should drive economic profits for at least the next 10 years.
The US contact lens market is controlled by four players. Johnson & Johnson makes up over one-third of the market, Alcon and Cooper both control roughly 25% each, and B&L controls 10%. B&L introduced the first contact lenses to the US in 1971, and it has continued investing ever since to launch more innovative products by dedicating roughly 8% of its sales on research and development year over year. In our opinion, it takes intensive research and development as well as technical know-how to develop and manufacture premium contact lenses that are difficult to replicate. We also believe B&L bolsters brand power through an evolutionary compounding of clinical and technical improvements in its products. All this effort by B&L reinforces positive perception within its practitioner base, which requires a lot of effort from a competitor to dismantle and convince otherwise.
We also see signs of switching costs in B&L’s lens business. In the US, a patient must get a prescription from an eye care professional, or ECP, to purchase contact lenses, and each prescription is brand-specific. Most ECPs stick with just one or two brands because they have strong relationships with manufacturers due to brand loyalty and rebates. They are also unlikely to mix brands because they want to stick with and prescribe products that they are familiar with. Each contact lens fits differently, and material behavior is different with all soft lenses, so once someone finds contact lenses that they enjoy wearing without any issues, it is highly likely that they will stick with the same ones year after year. And we see this in action—on average, a patient sticks with the same contact lenses for seven years. Contact lenses typically come in six- or 12-month supplies, creating further disincentives to switch brands frequently. Also, once customers are comfortable with a product, they are unlikely to switch lenses unless they are trading up for superior products (for example, switching from monofocal to multifocal or toric). In fact, the contact lens market is fairly resilient to macroeconomic conditions because contacts are seen as essential expenditures.
We believe B&L's consumer eye care products enjoy a narrow moat from intangible assets. In the lens care solutions space, B&L and Alcon control most of the market thanks to superior brand perception and product quality. Branded products such as B&L’s Biotrue hydration plus multipurpose solution are generally made with more up-to-date formulations compared with generic counterparts and have either low or no preservatives, leading to high customer preferences. In the over-the-counter eye care space, B&L has Lumify, a number one physician-recommended product in the eye redness reliever category. Since its 2018 launch, Lumify has gained share and now controls over half of the redness reliever market. And it was able to do this even at a price point that is much higher than the players that had existed prior to its launch—Lumify, on a dollar per milliliter basis, usually costs 5 times or more compared with its competitors. We attribute this to the product superiority and see this as another example of B&L’s proven track record of launching highly technical products.
Implantables is made up of a set of intraocular lenses, or IOLs, that tackle various vision-correcting needs. By our estimate, B&L controls a high-single-digit percentage of the IOL market. Unlike contact lenses that patients can try for themselves and pick a preferred option, doctors decide which intraocular lenses would be the most suitable for each case. And it is vital for doctors to be fully comfortable with the lenses they use, because a misplaced lens can cause blurred or double vision, swelling, and bleeding that require extra surgeries to correct. So we believe doctors having success with B&L’s IOLs would be reluctant to switch to another product and risk poor patient outcomes after surgery.
B&L’s equipment includes machines used to treat cataracts, refractive errors, and vitreoretinal disorders. We believe B&L controls roughly 20% of the installed base of phacoemulsification machines (used to remove cataracts) and vitrectomy machines. The life cycle for ophthalmic capital equipment is about 10 years, and equipment manufacturers generally launch new equipment in line with this life cycle (B&L launched the Millennium phaco system in 1997, Stellaris in 2007, and Stellaris Elite in 2017). In our view, Stellaris Elite offers no particular innovations that would allow B&L to take share from market leader Alcon, but the company is likely to maintain its share.
We don’t believe B&L’s ophthalmic pharmaceutical segment warrants a moat rating. More than half of the segment is driven by Miebo and Xiidra, two dry eye treatments, but the portfolio also includes a number of smaller branded and off-patent drugs. While we appreciate B&L for having a broad line of pharmaceuticals for a wide variety of eye conditions, we don’t currently see a moat in this business. The firm’s pipeline has improved over the past couple of years, and we do see a number of assets that could likely launch in the midterm, but the ophthalmic pharma market remains highly competitive, and we see limited upside to B&L coming up with potential blockbuster candidates.
Bull case
B&L has a strong commercial position in both contact lens and consumer eye care products, and this should drive solid growth over the long term.
B&L’s investment in its pharmaceutical portfolio over the past few years is paying off, with Miebo and Xiidra contributing nice growth to both top and bottom lines.
B&L's pipeline is filled with exciting launches across the portfolio, and we expect new launches every year for the next five years.
Bear case
B&L faces stiff competition across all segments that it plays in, and the lack of investment in its pipeline could leave the firm vulnerable to market share losses.
B&L’s full separation depends on its former parent company’s ability to deleverage, and this might interfere with B&L’s complete autonomy.
B&L’s balance sheet is significantly more leveraged compared with its key peers, which could put pressure on the firm’s ability to reinvest in its business and limit future capital-allocation priorities.
By Keonhee Kim, Zachary Cothran
Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.
Bausch + Lomb Corp. discussion 0 comments